News & Views - Page 12 of 54 - Telix Pharmaceuticals Limited

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

Telix today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC).

Activities Report and Appendix 4C for the quarter ended 30 September 2023

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.

Telix Quarterly Results and Investor Call / Webcast Notification

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October 2023.

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated.

Telix Half-Year Results 2023 and Investor Call / Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August 2023.

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.

Telix Quarterly Results and Investor Call / Webcast Notification

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market close.

Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical

Telix today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals.

Telix Urology Innovation Showcase – June 21, 2023, at The Yale Club, New York City

Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT and via live webcast (10.30pm AEST). The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures and will focus on:

First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Telix today announces that the first patient has been dosed in a global Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications.